A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma

Trial Profile

A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Everolimus (Primary) ; Panobinostat (Primary)
  • Indications Burkitt's lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoid leukaemia; Lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Feb 2018 Planned End Date changed from 1 Jan 2016 to 1 Dec 2018.
    • 05 Feb 2018 Planned End Date changed from 1 Jan 2016 to 1 Dec 2018.
    • 05 Feb 2018 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top